mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing Covid-19 illness
In short: A phase 3 randomized trial of 30,420 volunteers found that the mRNA-1273 vaccine was 94.1% effective at preventing symptomatic Covid-19. The study, which followed participants at high risk for infection, observed significantly fewer cases of illness and severe disease in those who received the two-dose vaccine regimen compared to a placebo group.
The trial was conducted across 99 centers in the United States, randomly assigning participants to receive either the vaccine or a placebo. While the results showed high efficacy and a similar rate of serious adverse events between groups, the researchers noted that more frequent moderate, transient reactions to the vaccine occurred compared to the placebo group.
Why it matters: The mRNA-1273 vaccine provides high protection against symptomatic and severe Covid-19 in high-risk populations.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Baden et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-mrna-1273-vaccine-demonstrated-94-1-efficacy-in-preventing-c.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics
